FDA Rejects Avastin for Late-Stage Breast Cancer

11/18/2011

After reviewing extensive research, the FDA has revoked its approval of Avastin for the treatment of breast cancer. The ruling followed the unanimous advice of a June 2011 advisory panel, which found that the cancer drug carries major risks but few benefits for women with late-stage breast cancer. Genentech, which makes Avastin, will continue their current study of Avastin in breast cancer patients to be completed in 2016. The drug is still available for treatment of other types of cancers. VIEW FULL ARTICLE